Department of Laboratory Medicine, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing 100730, China; Department of Pathology and Lab Medicine, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, 440 Jiyan Road, Jinan 250117, Shandong, China.
Department of Laboratory Medicine, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing 100730, China.
Ageing Res Rev. 2024 Nov;101:102485. doi: 10.1016/j.arr.2024.102485. Epub 2024 Sep 4.
Recently included in the 2024 new revised diagnostic criteria of Alzheimer's disease (AD), glial fibrillary acidic protein (GFAP) has garnered significant attention. A systematic review and meta-analysis were performed to comprehensively evaluate the diagnostic, differential diagnostic, and prospective diagnostic performance of GFAP in cerebrospinal fluid (CSF) and blood for AD continuum. A literature search using common electronic databases, important websites and historical search way was performed from inception to the beginning of March 2023. The inclusion criteria was studies evaluating the diagnostic accuracy of GFAP in CSF and/or blood for the AD continuum patients, utilizing PET scans, CSF biomarkers and/or clinical criteria. The systematic review and meta-analysis were conducted referring to the Cochrane Handbook. In total, 34 articles were eventually included in the meta-analysis, 29 of which were published within the past three years. Blood GFAP exhibited good diagnostic accuracy across various AD continuum patients, and the summary area under curve for distinguishing PET positive and negative individuals, CSF biomarkers defined positive and negative individuals, clinically diagnosed AD and cognitive unimpaired controls, AD and/or mild cognitive impairment and other neurological diseases, and prospective cases and controls was 0.85[0.81-0.88], 0.77[0.73-0.81], 0.92[0.90-0.94], 0.80[0.77-0.84], and 0.79[0.75-0.82], respectively. Only several studies were recognized to evaluate the diagnostic accuracy of CSF GFAP, which was not as good as that of blood GFAP (paired mixed data: AUC = 0.86 vs. AUC = 0.77), but its accuracy remarkably increased to AUC = 0.91 when combined with other factors like sex, age, and ApoE genotype. In summary, GFAP, particularly in blood, shown good diagnostic, differential diagnostic, and prospective diagnostic accuracy for AD continuum patients, with improved accuracy when used alongside other basic indexes.
最近,神经原纤维酸性蛋白(GFAP)被纳入 2024 年阿尔茨海默病(AD)新修订的诊断标准,受到了广泛关注。我们进行了一项系统评价和荟萃分析,以全面评估 GFAP 在脑脊液(CSF)和血液中用于 AD 连续体的诊断、鉴别诊断和前瞻性诊断性能。我们从研究开始到 2023 年 3 月初,使用常见的电子数据库、重要网站和历史检索方法进行了文献检索。纳入标准为评估 GFAP 在 CSF 和/或血液中用于 AD 连续体患者的诊断准确性的研究,使用 PET 扫描、CSF 生物标志物和/或临床标准。系统评价和荟萃分析参照 Cochrane 手册进行。最终,共有 34 篇文章纳入荟萃分析,其中 29 篇发表于过去三年。血液 GFAP 在各种 AD 连续体患者中具有良好的诊断准确性,用于区分 PET 阳性和阴性个体、CSF 生物标志物定义的阳性和阴性个体、临床诊断的 AD 和认知正常对照者、AD 和/或轻度认知障碍及其他神经退行性疾病,以及前瞻性病例和对照者的汇总曲线下面积分别为 0.85[0.81-0.88]、0.77[0.73-0.81]、0.92[0.90-0.94]、0.80[0.77-0.84]和 0.79[0.75-0.82]。只有少数研究评估了 CSF GFAP 的诊断准确性,其诊断准确性不如血液 GFAP(配对混合数据:AUC=0.86 与 AUC=0.77),但当与性别、年龄和 ApoE 基因型等其他因素相结合时,其准确性显著提高至 AUC=0.91。综上所述,GFAP,尤其是血液中的 GFAP,对 AD 连续体患者具有良好的诊断、鉴别诊断和前瞻性诊断准确性,与其他基本指标联合使用可提高准确性。